mRNA-1083联合疫苗在≥50岁日本成人中的免疫原性、反应原性与安全性
这项3期随机观察者盲法研究(日本部分)纳入≥50岁成人,比较mRNA-1083联合疫苗与日本许可流感HA疫苗加mRNA-1273的免疫原性、反应原性与安全性。第29天mRNA-1083对全部评估流感株和SARS-CoV-2诱导非劣效免疫应答,总体人群中对照匹配流感株和SARS-CoV-2达优效;高危人群对照匹配株达非劣效。第181天免疫应答仍高于基线,安全性可接受。
要点
- mRNA-1083在第29天对全部评估流感株和SARS-CoV-2达非劣效,总体人群对照匹配株达优效。
- 高危人群(≥65岁及60–<65岁伴≥1合并症)对照匹配流感株和SARS-CoV-2达非劣效。
- 第181天免疫应答仍高于基线,多数征集性不良反应为1或2级,未见心肌炎/心包炎及与研究干预相关严重不良事件或死亡。
核心结论
- mRNA-1083在≥50岁成人中安全性可接受,对流感与SARS-CoV-2诱导非劣效(高危人群对照匹配株)和优效(总体人群对照匹配株)免疫应答,并维持至接种后6个月。
研究设计与样本
- 3期、亚太地区、随机、观察者盲法研究日本部分(Part 1),评估mRNA-1083联合流感与SARS-CoV-2抗原的免疫原性、反应原性与安全性。
- ≥50岁参与者按1:1随机接受mRNA-1083+安慰剂或日本许可流感HA疫苗+mRNA-1273,共2022例随机、2013例接受研究干预。
主要发现
- 第29天mRNA-1083对全部评估流感株和SARS-CoV-2的免疫应答非劣效于活性对照。
- 高危参与者(≥65岁及60–<65岁伴≥1合并症)中,mRNA-1083对对照匹配流感株和SARS-CoV-2达非劣效。
- 总体研究人群中,mRNA-1083对对照匹配流感株和SARS-CoV-2达优效。
- 第181天免疫应答仍高于基线,与活性对照相当或数值更高。
- 多数征集性不良反应为1或2级,无心肌炎或心包炎病例,无与研究干预相关严重不良事件或死亡报告。
关键数值与推荐
- 第29天mRNA-1083对全部评估流感株和SARS-CoV-2免疫应答非劣效于活性对照。
- 高危人群中mRNA-1083对对照匹配流感株和SARS-CoV-2达非劣效。
- 总体人群中mRNA-1083对对照匹配流感株和SARS-CoV-2达优效。
- 第181天免疫应答仍高于基线且与活性对照相当或数值更高。
临床怎么用
- 结果支持mRNA-1083作为≥50岁成人单剂季节性流感与SARS-CoV-2联合疫苗接种方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A multicomponent vaccine targeting seasonal influenza and coronavirus disease 2019 (COVID-19) may reduce disease burden by providing simultaneous protection in a single injection. We report findings from Part 1 (Japan) of a phase 3, Asia-Pacific, randomized, observer-blind study evaluating immunogenicity, reactogenicity, and safety of mRNA-based multicomponent vaccine mRNA-1083, combining influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens. Participants aged ≥50 years were randomized (1:1) to receive mRNA-1083 + placebo or Japan-licensed influenza hemagglutinin (HA) vaccine + mRNA-1273. Overall, 2022 participants were randomized, and 2013 received study intervention. At Day 29, mRNA-1083 elicited noninferior immune responses versus active comparators for all evaluated influenza strains and SARS-CoV-2. Among high-risk participants (aged ≥65 years and 60 to <65 years with ≥1 comorbidity), noninferiority of mRNA-1083 was demonstrated for comparator-matched influenza strains and SARS-CoV-2. In the overall study population, mRNA-1083 demonstrated superiority for the comparator-matched influenza strains and for SARS-CoV-2. At Day 181, immune responses remained above baseline and were comparable to or numerically higher than those elicited by active comparators. Most solicited adverse reactions were grade 1 or 2. There were no cases of myocarditis or pericarditis, and no reported serious adverse events or deaths related to study intervention. Overall, mRNA-1083 demonstrated an acceptable safety profile, eliciting noninferior and superior immune responses against influenza and SARS-CoV-2 in the high-risk and overall study population, respectively. Immune responses were maintained through 6 months post-vaccination. These findings support mRNA-1083 as a single-dose approach to seasonal vaccination against influenza and SARS-CoV-2 in adults ≥50 years. ClinicalTrials.govidentifier: NCT06694389 (https://clinicaltrials.gov/study/NCT06694389).
引用
- Kostanyan L, Fukase H, Rumyantsev A, et al. Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan. Vaccine. 2026. PMID: 42531981. doi:10.1016/j.vaccine.2026.128961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。